Fibroblast growth factor 23 and the heart

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 4, 2012, Pages 369-375

  Faul, Christian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

calcineurin; cardiorenal syndrome; fibroblast growth factor receptor signaling; left ventricular hypertrophy

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; HEART RECEPTOR; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MYOCARDIUM; PROGNOSIS; SIGNAL TRANSDUCTION; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84862122363     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835422c4     Document Type: Review

References (67)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. NHLBI. Working Group: Cardio-renal connections in heart failure and cardiovascular disease, http://www.Nhlbi.Nih.Gov/meeting/workshop/cardiorenalhf- hd.htm. [Accessed 2004]
3. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52:1527-1539.
4. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74:148-157. (Pubitemid 351915080)
5. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75:890-897.
6. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118:3820-3828.
7. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
8. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
9. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
10. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
11. Stevens KK, McQuarrie EP, Sands W, et al. Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation. Int J Nephrol 2011:297070.
12. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial Int 2012; 16:53-58.
13. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337: 116-122.
14. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20:563-569. (Pubitemid 39314564)
15. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086. (Pubitemid 33070451)
16. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-149. (Pubitemid 40616112)
17. McKeehan WL, Kan M. Heparan sulfate fibroblast growth factor receptor complex: structure-function relationships. Mol Reprod Dev 1994; 39:69-81.
18. Bellot F, Crumley G, Kaplow JM, et al. Ligand-induced transphosphorylation between different FGF receptors. EMBO J 1991; 10:2849-2854. (Pubitemid 21905302)
19. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500-6505. (Pubitemid 32488266)
20. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klothodependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417-3428. (Pubitemid 46685217)
21. Harmer NJ, Pellegrini L, Chirgadze D, et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43:629-640. (Pubitemid 38114050)
22. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16:107-137. (Pubitemid 40616111)
23. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774. (Pubitemid 44949607)
24. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120-6123. (Pubitemid 43847540)
25. Tohyama O, Imura A, Iwano A, et al. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004; 279: 9777-9784. (Pubitemid 38372575)
26. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51. (Pubitemid 27494749)
27. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008. (Pubitemid 350224109)
28. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95:578-585.
29. Yamazaki M, Ozono K, Okada T, et al. Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells. J Cell Biochem 2010; 111:1210-1221.
30. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358:1370-1380.
31. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7:589-600. (Pubitemid 44325350)
32. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115:527-537. (Pubitemid 40322222)
33. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 2004; 63:467-475. (Pubitemid 38970191)
34. Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (London) 2008; 115:203-218.
35. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth and function by calcineurin signaling. J Biol Chem 2003; 278:36981-36984. (Pubitemid 37175209)
36. Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science 2008; 322:1494-1497.
37. Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke 'fetal' contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990; 85:507-514. (Pubitemid 20070059)
38. Kardami E, Jiang ZS, Jimenez SK, et al. Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc Res 2004; 63:458-466. (Pubitemid 38970190)
39. Bogoyevitch MA, Glennon PE, Andersson MB, et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994; 269:1110-1119.
40. Kaye D, Pimental D, Prasad S, et al. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest 1996; 97:281-291.
41. Scheinowitz M, Kotlyar A, Zimand S, et al. Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats. Exp Physiol 1998; 83:585-593. (Pubitemid 28458390)
42. Schultz JE, Witt SA, Nieman ML, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 1999; 104:709-719. (Pubitemid 29536356)
43. House SL, House BE, Glascock B, et al. Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. Mol Cell Pharmacol 2010; 2:143-154.
44. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010; 225:631-637.
45. Virag JA, Rolle ML, Reece J, et al. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007; 171:1431-1440. (Pubitemid 350158305)
46. Laham RJ, Chronos NA, Pike M, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000; 36:2132-2139.
47. Jiang ZS, Srisakuldee W, Soulet F, et al. Nonangiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 2004; 62:154-166. (Pubitemid 38326821)
48. Htun P, Ito WD, Hoefer IE, et al. Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium. J Mol Cell Cardiol 1998; 30:867-877. (Pubitemid 28190731)
49. Horrigan MC, Malycky JL, Ellis SG, et al. Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. Int J Cardiol 1999; 68 (Suppl 1):S85-S91. (Pubitemid 29197202)
50. House SL, Bolte C, Zhou M, et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003; 108:3140-3148. (Pubitemid 38031805)
51. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 45:1005-1019. (Pubitemid 27284024)
52. Izumo S, Lompre AM, Matsuoka R, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 1987; 79:970-977. (Pubitemid 17050926)
53. Lompre AM, Mercadier JJ, Schwartz K. Changes in gene expression during cardiac growth. Int Rev Cytol 1991; 124:137-186.
54. Schwartz K, de la Bastie D, Bouveret P, et al. Alpha-skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts. Circ Res 1986; 59:551-555. (Pubitemid 17000931)
55. Schoenfeld JR, Vasser M, Jhurani P, et al. Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol 1998; 30:2269-2280. (Pubitemid 28549979)
56. Kagiyama S, Eguchi S, Frank GD, et al. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106:909-912. (Pubitemid 34925322)
57. Di Marco GS, Reuter S, Kentrup D, et al. Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. Eur Heart J 2010; 32:1935-1945.
58. Finch JL, Tokumoto M, Nakamura H, et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298:F1315-F1322.
59. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17:5896-5904. (Pubitemid 28474784)
60. Lowrie EG, Huang WH, Lew NL. Death risk predictors among peritoneal dialysis and hemodialysis patients: a preliminary comparison. Am J Kidney Dis 1995; 26:220-228.
61. Zager PG, Nikolic J, Brown RH, et al. 'U' curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic Inc. Kidney Int 1998; 54:561-569. (Pubitemid 28357420)
62. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370-1378.
63. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2009; 95:578-585.
64. Tomono M, Toyoshima K, Ito M, Amano H. Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. Biochem J 1996; 317 (Pt 3):675-680. (Pubitemid 26308237)
65. Boxer AL, Moreno H, Rudy B, Ziff EB. FGF-2 potentiates Ca-dependent inactivation of NMDA receptor currents in hippocampal neurons. J Neurophysiol 1999; 82:3367-3377. (Pubitemid 30017461)
66. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004; 322:1178-1191. (Pubitemid 39164648)
67. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65:45-79. (Pubitemid 38249147)